Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | BDKRB2 | P30411 | 15/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659166 | 0.84 | MAPT (0.50) | MAPTL3MBTL1BDKRB2MAPK1TDP1 | |
| SCHEMBL6642612 | 0.83 | MAPT (0.49) | MAPTL3MBTL1BDKRB2MAPK1TDP1 | |
| SCHEMBL6643771 | 0.82 | L3MBTL1 (0.48) | MAPTL3MBTL1BDKRB2MAPK1TDP1 | |
| SCHEMBL3051014 | 0.81 | MAPT (0.50) | MAPTL3MBTL1BDKRB2 | |
| SCHEMBL6596560 | 0.81 | HPGD (0.51) | MAPTMEN1KMT2A | |
| SCHEMBL6642784 | 0.81 | LMNA (0.47) | MAPTL3MBTL1BDKRB2MAPK1TDP1 | |
| SCHEMBL6640544 | 0.81 | PTGER1 (0.52) | MAPTL3MBTL1MAPK1TDP1ADORA3 | |
| SCHEMBL6639484 | 0.81 | MAPT (0.50) | MAPTL3MBTL1BDKRB2MAPK1TDP1 | |
| SCHEMBL3046044 | 0.80 | CD38 (0.61) | BDKRB2 | |
| SCHEMBL6080000 | 0.79 | NOTUM (0.51) | MAPTTDP1ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | MAPT 2300/4885L3MBTL1 4478/4885BDKRB2 1/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | MAPT 2300/4885L3MBTL1 4478/4885BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.